Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Carlos Schuler
AddedFeb 13, 2024
UpdatedMay 31, 2026
Carlos Schuler

Carlos Schuler

Co-Founder, InCarda Therapeutics

LinkedInThe Org

Carlos Schuler's Career

InCarda Therapeutics
InCarda Therapeutics

Newark, CA, US

Co-Founder
ViaCyte
ViaCyte

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Carlos Schuler's Career

InCarda Therapeutics
InCarda Therapeutics
Series A$86.4M102009Newark, CA, US
Co-Founder

Leadership at InCarda Therapeutics

George BickerstaffGeorge BickerstaffBoard Member
Gregory M. MarcusGregory M. MarcusCo-Founder
Adam FreundAdam FreundCo-Founder
Narsi RangachariNarsi RangachariCo-Founder
Robert LisickiRobert LisickiCEO
Alan ColowickAlan ColowickBoard Member

Similar to InCarda Therapeutics

Cardeas PharmaCardeas PharmaSeattle, WA, USAntibiotics, Pharmaceuticalsest. 2010Cardeas PharmaSeattle, WA, US · est. 2010

Cardeas Pharma: Specializing in developing inhaled antibiotics for respiratory infections.

Series B · $80M30
BioCardiaBioCardiaSan Carlos, CA, USMedical Devices, Therapeuticsest. 1999BioCardiaSan Carlos, CA, US · est. 1999

BioCardia, a San Carlos-based medical firm, develops innovative regenerative therapies for critical cardiovascular diseases.

Public · $41.3M28
Respira TherapeuticsRespira TherapeuticsAlbuquerque, NM, USDrug Delivery, Inhalationest. 2010Respira TherapeuticsAlbuquerque, NM, US · est. 2010

Respira: A drug delivery tech company specializing in efficient dry powder inhaler technologies.

Series B · $5.1M9
Cardurion PharmaceuticalsCardurion PharmaceuticalsBurlington, MA, USTherapeuticsest. 2017Cardurion PharmaceuticalsBurlington, MA, US · est. 2017

Boston-based biotech firm specializing in next-gen therapeutics for heart diseases.

Series B · $343.1M42
ViaCyte
ViaCyte
Public$235.5M1751999San Diego, CA, US
Board Member· Board

Leadership at ViaCyte

Fred MiddletonFred MiddletonBoard Member
Paul LaikindPaul LaikindFounder
Michael YangMichael YangCEO

Similar to ViaCyte

CelularityCelularityFlorham Park, NJ, USCell Therapiesest. 2016CelularityFlorham Park, NJ, US · est. 2016

Celularity, a US-based biotech firm, pioneers in delivering large-scale, quality allogeneic placenta-derived cellular therapies.

Public · $400M225
Pathfinder Cell TherapyPathfinder Cell TherapyCambridge, MA, USCell Therapyest. 2007Pathfinder Cell TherapyCambridge, MA, US · est. 2007

Pathfinder Cell Therapy: Innovating cell-based treatments for organ-specific diseases and damage.

1
Cell Care TherapeuticsCell Care TherapeuticsMonrovia, CA, USBiopharmaceuticalsest. 2014Cell Care TherapeuticsMonrovia, CA, US · est. 2014

Cell Care Therapeutics: A California-based biopharmaceutical firm specializing in regenerative immunotherapies.

Seed · $5.3M7
SymbioCellTechSymbioCellTechSalt Lake City, UT, USCell Therapyest. 2006SymbioCellTechSalt Lake City, UT, US · est. 2006

SymbioCellTech: A biotech firm innovating cell therapy for long-term control of Type 1 Diabetes.

Series A · $15.5M8

Carlos Schuler's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Carlos Schuler

Daniel WelchDaniel WelchBoard Member · Ultragenyx PharmaceuticalMohamed Sadeq AliMohamed Sadeq AliCo-Founder · Root NYCMatt AhrensMatt AhrensCo-Founder · Cadi